To further evaluate the performance of the screen, we assessed the enrichment of gRNAs targeting well-characterised 6-TG sensitivity genes HPRT1 and NUDT5 [44], as well as those in the mismatch repair pathway [7], in treated tumours. Here, NUDT5 is linked to neoplasm.